After the US slashed global aid, the South African government stated that only 17% of its HIV spending relied on US funding. But some experts argue that US health initiatives had more bang for buck than the government’s programmes. Jesse Copelyn looks past the 17% figure, and considers how the health system is being affected by the loss of US money.
Recent media reports over the future of NHI have been contradictory and hard to make sense of. Chris Bateman chased up those in a position to know where things stand – it seems the ANC has not in fact made any major concessions on NHI. There is however agreement that medical schemes won’t be phased out in the next few years, something that likely wouldn’t have happened in any case given the poor state of the economy and the long timeline for NHI implementation.
South Africa’s National Department of Health is still to outline a clear contingency plan as a US funding freeze puts lives at risk, spells job losses, and presents threats to keeping HIV and TB under control. Ufrieda Ho reports.
The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, access to these medicines remain limited in South Africa. Catherine Tomlinson asks which of the GLP-1 agonists are available here and at what price.
Whether or not the ANC and DA can find common ground on the future of medical schemes is set to be a major test of South Africa’s Government of National Unity. Ahead of a Cabinet lekgotla where the issue is expected to be on the agenda, momentum has been gathering behind a compromise option. Chris Bateman reports.
In 2023, tuberculosis was again the top infectious disease killer on the planet, having temporarily been overtaken by COVID-19. Even so, investment in TB research is far below what United Nations agencies estimate is needed. Catherine Tomlinson unpacks a new report on global TB research funding, zooming in on the situation in South Africa.
Highly effective treatments for HIV have existed since the mid-1990s. But while these treatments keep people healthy, we do not yet have a safe and scalable way to completely rid the body of the virus. In this Spotlight special briefing, Elri Voigt takes stock of where we are in the decades-long search for an HIV cure.
Some patients at KwaZulu-Natal hospitals are donating lung tissue for use in TB research. Sue Segar tracks what happens to these tissue samples and explores why these samples are so important to unlocking the mysteries of what the TB bacterium does inside the human body.
An estimated 56 000 people in South Africa and 1.25 million around the world died of TB in 2023, according to just-published figures from the WHO. This means that in 2023 TB overtook COVID-19 as the top infectious disease killer on the planet. Marcus Low unpacks the new numbers.
Pregnant women are typically excluded from clinical trials of new TB medicines. This has led to a lack of solid scientific evidence on how best to treat women who fall ill with TB while they are expecting. Tiyese Jeranji asked local TB experts about the problem and puts the spotlight on a recent study that broke the mould by opening its doors to pregnant women.
Hillbrow started out as Johannesburg’s first health hub in the late 1880s. It’s also been a suburb associated with pimps and prostitution, a middle finger to the Nationalist Party, and a key site of the HIV crisis. Today, it’s the forgotten flatlands of inner city decay … but in small pockets it stays true to its heritage of bringing healthcare to the city’s most overlooked.
In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works. Elri Voigt goes over the new findings and unpacks the licenses that are expected to facilitate the availability of generic versions of the jab in over a hundred countries, including South Africa.
